	US 12,257,286 B2
	Methods and materials for treating cancer
Saad J. Kenderian, Rochester, MN (US); Neil E. Kay, St. Louis Park, MN (US); Michelle J. Cox, Rochester, MN (US); and Fabrice Lucien-Matteoni, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/288,212
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Oct. 31, 2019, PCT No. PCT/US2019/059113 § 371(c)(1), (2) Date Apr. 23, 2021, PCT Pub. No. WO2020/092736, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/753,662, filed on Oct. 31, 2018.
Prior Publication US 2021/0401886 A1, Dec. 30, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 14/725 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)

CPC A61K 38/1774 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61P 35/02 (2018.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05)]

8 Claims

1. A method for treating a mammal having cluster of differentiation 19 (CD19) positive (CD19⁺) cancer, wherein said method comprises:

(a) assessing extracellular vesicles (EVs) of a tumor microenvironment of said cancer to identify said mammal as being either a mammal having EVs that are CD19⁺ or a mammal having EVs that are CD19 negative (CD19⁻);

(b) identifying said mammal as being said mammal having EV that are CD19⁻; and